Precancerous  ||| S:0 E:13 ||| JJ
conditions  ||| S:13 E:24 ||| NNS
and  ||| S:24 E:28 ||| CC
risk  ||| S:28 E:33 ||| NN
factors  ||| S:33 E:41 ||| NNS
for  ||| S:41 E:45 ||| IN
pancreatic  ||| S:45 E:56 ||| NN
and  ||| S:56 E:60 ||| CC
bile  ||| S:60 E:65 ||| JJ
duct  ||| S:65 E:70 ||| JJ
cancer  ||| S:70 E:77 ||| NN
Pancreatic  ||| S:77 E:88 ||| NNP
cancer  ||| S:88 E:95 ||| NN
has  ||| S:95 E:99 ||| VBZ
one  ||| S:99 E:103 ||| CD
of  ||| S:103 E:106 ||| IN
the  ||| S:106 E:110 ||| DT
worst  ||| S:110 E:116 ||| JJS
prognoses  ||| S:116 E:126 ||| NN
of  ||| S:126 E:129 ||| IN
any  ||| S:129 E:133 ||| DT
type  ||| S:133 E:138 ||| NN
of  ||| S:138 E:141 ||| IN
cancer ||| S:141 E:147 ||| NN
.  ||| S:147 E:149 ||| .
Early  ||| S:149 E:155 ||| JJ
detection  ||| S:155 E:165 ||| NN
and  ||| S:165 E:169 ||| CC
surgery  ||| S:169 E:177 ||| NN
is  ||| S:177 E:180 ||| VBZ
the  ||| S:180 E:184 ||| DT
best  ||| S:184 E:189 ||| JJS
chance  ||| S:189 E:196 ||| NN
for  ||| S:196 E:200 ||| IN
cure ||| S:200 E:204 ||| NN
.  ||| S:204 E:206 ||| .
However ||| S:206 E:213 ||| RB
,  ||| S:213 E:215 ||| ,
symptoms  ||| S:215 E:224 ||| NNS
are  ||| S:224 E:228 ||| VBP
typically  ||| S:228 E:238 ||| RB
vague  ||| S:238 E:244 ||| JJ
and  ||| S:244 E:248 ||| CC
occur  ||| S:248 E:254 ||| VB
when  ||| S:254 E:259 ||| WRB
the  ||| S:259 E:263 ||| DT
cancer  ||| S:263 E:270 ||| NN
is  ||| S:270 E:273 ||| VBZ
unresectable ||| S:273 E:285 ||| VBN
.  ||| S:285 E:287 ||| .
Early  ||| S:287 E:293 ||| JJ
detection  ||| S:293 E:303 ||| NN
through  ||| S:303 E:311 ||| IN
screening  ||| S:311 E:321 ||| NN
is  ||| S:321 E:324 ||| VBZ
likely  ||| S:324 E:331 ||| JJ
to  ||| S:331 E:334 ||| TO
be  ||| S:334 E:337 ||| VB
the  ||| S:337 E:341 ||| DT
best  ||| S:341 E:346 ||| JJS
hope  ||| S:346 E:351 ||| NN
to  ||| S:351 E:354 ||| TO
improve  ||| S:354 E:362 ||| VB
survival ||| S:362 E:370 ||| NN
.  ||| S:370 E:372 ||| .
The  ||| S:372 E:376 ||| DT
relatively  ||| S:376 E:387 ||| RB
low  ||| S:387 E:391 ||| JJ
incidence  ||| S:391 E:401 ||| NN
of  ||| S:401 E:404 ||| IN
pancreatic  ||| S:404 E:415 ||| JJ
cancer  ||| S:415 E:422 ||| NN
and  ||| S:422 E:426 ||| CC
the  ||| S:426 E:430 ||| DT
insensitive  ||| S:430 E:442 ||| JJ
screening  ||| S:442 E:452 ||| NN
techniques  ||| S:452 E:463 ||| NNS
currently  ||| S:463 E:473 ||| RB
available  ||| S:473 E:483 ||| JJ
render  ||| S:483 E:490 ||| NNS
this  ||| S:490 E:495 ||| DT
approach  ||| S:495 E:504 ||| NN
expensive  ||| S:504 E:514 ||| JJ
and  ||| S:514 E:518 ||| CC
inefficient  ||| S:518 E:530 ||| JJ
in  ||| S:530 E:533 ||| IN
the  ||| S:533 E:537 ||| DT
general  ||| S:537 E:545 ||| JJ
population ||| S:545 E:555 ||| NN
.  ||| S:555 E:557 ||| .
Early  ||| S:557 E:563 ||| JJ
detection  ||| S:563 E:573 ||| NN
and  ||| S:573 E:577 ||| CC
screening  ||| S:577 E:587 ||| NN
for  ||| S:587 E:591 ||| IN
pancreatic  ||| S:591 E:602 ||| JJ
cancer  ||| S:602 E:609 ||| NN
in  ||| S:609 E:612 ||| IN
the  ||| S:612 E:616 ||| DT
current  ||| S:616 E:624 ||| JJ
state  ||| S:624 E:630 ||| NN
should  ||| S:630 E:637 ||| MD
be  ||| S:637 E:640 ||| VB
limited  ||| S:640 E:648 ||| VBN
to  ||| S:648 E:651 ||| TO
highrisk  ||| S:651 E:660 ||| VB
patiens ||| S:660 E:667 ||| NNS
.  ||| S:667 E:669 ||| .
But  ||| S:669 E:673 ||| CC
hereditary  ||| S:673 E:684 ||| JJ
factors  ||| S:684 E:692 ||| NNS
account  ||| S:692 E:700 ||| VBP
about  ||| S:700 E:706 ||| RB
10 ||| S:706 E:708 ||| CD
%  ||| S:708 E:710 ||| NN
of  ||| S:710 E:713 ||| IN
patients  ||| S:713 E:722 ||| NNS
with  ||| S:722 E:727 ||| IN
pancreatic  ||| S:727 E:738 ||| JJ
cancer  ||| S:738 E:745 ||| NN
( ||| S:745 E:746 ||| -LRB-
familial  ||| S:746 E:755 ||| JJ
pancreatic  ||| S:755 E:766 ||| JJ
cancer ||| S:766 E:772 ||| NN
,  ||| S:772 E:774 ||| ,
hereditary  ||| S:774 E:785 ||| JJ
pancreatitis ||| S:785 E:797 ||| NN
,  ||| S:797 E:799 ||| ,
Peutzâ€Š ||| S:799 E:805 ||| FW
Jeghers  ||| S:805 E:813 ||| FW
syndrom  ||| S:813 E:821 ||| FW
etc. ||| S:821 E:825 ||| FW
) ||| S:825 E:826 ||| -RRB-
.  ||| S:826 E:828 ||| .
Continued  ||| S:828 E:838 ||| JJ
efforts  ||| S:838 E:846 ||| NNS
are  ||| S:846 E:850 ||| VBP
needed  ||| S:850 E:857 ||| VBN
to  ||| S:857 E:860 ||| TO
discover  ||| S:860 E:869 ||| VB
effective  ||| S:869 E:879 ||| JJ
test  ||| S:879 E:884 ||| NN
to  ||| S:884 E:887 ||| TO
identify  ||| S:887 E:896 ||| VB
patients  ||| S:896 E:905 ||| NNS
with  ||| S:905 E:910 ||| IN
nonhereditary  ||| S:910 E:924 ||| JJ
risk  ||| S:924 E:929 ||| NN
factors  ||| S:929 E:937 ||| NNS
who  ||| S:937 E:941 ||| WP
will  ||| S:941 E:946 ||| MD
benefit  ||| S:946 E:954 ||| VB
from  ||| S:954 E:959 ||| IN
screening  ||| S:959 E:969 ||| NN
and  ||| S:969 E:973 ||| CC
also  ||| S:973 E:978 ||| RB
to  ||| S:978 E:981 ||| TO
develop  ||| S:981 E:989 ||| VB
less  ||| S:989 E:994 ||| JJR
invasive  ||| S:994 E:1003 ||| NNS
and  ||| S:1003 E:1007 ||| CC
more  ||| S:1007 E:1012 ||| RBR
costeffective  ||| S:1012 E:1026 ||| JJ
screening  ||| S:1026 E:1036 ||| NN
modalities  ||| S:1036 E:1047 ||| VBZ
aimed  ||| S:1047 E:1053 ||| VBN
at  ||| S:1053 E:1056 ||| IN
controlling  ||| S:1056 E:1068 ||| VBG
pancreatic  ||| S:1068 E:1079 ||| JJ
cancer ||| S:1079 E:1085 ||| NN
.  ||| S:1085 E:1087 ||| .
A  ||| S:1087 E:1089 ||| DT
combined  ||| S:1089 E:1098 ||| JJ
ap-proach  ||| S:1098 E:1108 ||| NN
of  ||| S:1108 E:1111 ||| IN
serum  ||| S:1111 E:1117 ||| JJ
markers ||| S:1117 E:1124 ||| NN
,  ||| S:1124 E:1126 ||| ,
genetic  ||| S:1126 E:1134 ||| JJ
markers  ||| S:1134 E:1142 ||| NN
and  ||| S:1142 E:1146 ||| CC
specific  ||| S:1146 E:1155 ||| JJ
imaging  ||| S:1155 E:1163 ||| NN
studies  ||| S:1163 E:1171 ||| NNS
may  ||| S:1171 E:1175 ||| MD
prove  ||| S:1175 E:1181 ||| VB
to  ||| S:1181 E:1184 ||| TO
be  ||| S:1184 E:1187 ||| VB
the  ||| S:1187 E:1191 ||| DT
future  ||| S:1191 E:1198 ||| NN
of  ||| S:1198 E:1201 ||| IN
pancreatic  ||| S:1201 E:1212 ||| JJ
screening ||| S:1212 E:1221 ||| NN
.  ||| S:1221 E:1223 ||| .
